Омега-3 жирные кислоты для Телогеновый эффлувиум
B Доказательства По меньшей мере одно рандомизированное исследование подтверждает это, с в целом согласованными результатами.На основе 11 исследований с участием 317 участников. 8/11 исследований показывают положительные эффекты.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'haircited.com';
const params = 'ingredient\u003Domega\u002D3\u0026condition\u003Dtelogen\u002Deffluvium';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
Итог
Moderate evidence suggests that omega-3 fatty acids may help support hair recovery in telogen effluvium, though the research base is limited and they are usually studied alongside other nutrients.
- 8 out of 11 studies show positive effects, but total sample size is small (317 participants)
- Often studied as part of multi-nutrient supplement formulations
- No large-scale RCTs specifically for omega-3 and telogen effluvium
- May support recovery through anti-inflammatory and nutritional mechanisms
Key Study Findings
review
Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.
Dose: Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5
или: Placebo
Эффект: Comparable efficacy to topical minoxidil; hypertrichosis 24%, shedding 16-22%, peripheral edema 2%
None
narrative review
Herbal Remedies for Hair Loss: A Review of Efficacy and Safety.
Dose: varies by remedy and study
или: Placebo
Эффект: None
None
scoping_review
n=16
A Scoping Review of Exosome Delivery Applications in Hair Loss.
Dose: variable; exosomes predominantly from mesenchymal stem cells (MSCs)
или: Placebo
Эффект: None
None
review
The Use of Light-Based Therapies in the Treatment of Alopecia.
Dose: Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri
или: Placebo
Эффект: LLLT improves hair density in AGA; potential to prolong anagen phase in telogen effluvium; may promo
None
Cohort
n=200
Open-label
Iron Supplementation May Improve the Patient's Level of Satisfaction in Not-Low-Ferritin Telogen Effluvium: A Real-Life …
Dose: high dose elemental iron (dose unspecified)
или: Placebo
Эффект: Patients with baseline ferritin ≥50 ng/ml mostly 'very satisfied'; patients with ferritin <50 ng/ml
None
clinical trial (open-label)
Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with …
Dose: None
или: Placebo
Эффект: None
None
Key Statistics
11
Исследования
317
Участники
↑
Positive
B
Оценка
Referenced Papers
American journal of …
2026
1 цитирований
Cureus
2025
7 цитирований
Skin appendage disorders
2025
7 цитирований
Journal of cosmetic …
2025
Indian journal of …
2024
4 цитирований
Journal of cosmetic …
2023
6 цитирований
Journal of cosmetic …
2022
30 цитирований
NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India.
Observational
Journal of cosmetic …
2019
25 цитирований
Acta dermatovenerologica Croatica …
2016
6 цитирований
Georgian medical news
2007
Therapeutische Umschau. Revue …
2002
4 цитирований
Dermatologic clinics
1993
38 цитирований
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Часто используемые дозировки
- general:
- 250-500 mg EPA+DHA/day
- hairloss:
- 1,000-2,000 mg/day
Верхний предел: 3,000 mg/day EPA+DHA
Дозировки, изученные в исследованиях
| Дозировка | Длительность | Эффект | N |
|---|---|---|---|
| Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 | -- | Positive | -- |
| varies by remedy and study | -- | Positive | -- |
| variable; exosomes predominantly from mesenchymal stem cells (MSCs) | -- | Positive | 16 |
| Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri | -- | Positive | -- |
| high dose elemental iron (dose unspecified) | -- | Positive | 200 |
| None | -- | Positive | -- |
| None | -- | Neutral | 100 |
| psychiatric and dermatological management | -- | Neutral | 1 |
Лучшее время приёма: With meals containing fat for optimal absorption; split doses if over 1,000 mg
Safety & Side Effects
Зарегистрированные побочные эффекты
- ⚠ Fishy aftertaste or burping
- ⚠ Mild gastrointestinal upset (nausea, diarrhea)
- ⚠ Possible increased bleeding time at high doses
- ⚠ Unpleasant body odor at very high doses
Известные взаимодействия
- ● Anticoagulants (warfarin) and antiplatelet drugs (may increase bleeding risk)
- ● Blood pressure medications (additive hypotensive effect)
- ● Orlistat (reduces omega-3 absorption)
Допустимый верхний уровень потребления: 3,000 mg/day EPA+DHA
Всегда консультируйтесь с врачом перед началом приёма любых добавок.Всегда консультируйтесь с лечащим врачом перед началом приёма любой добавки.
Frequently Asked Questions
Does Омега-3 жирные кислоты help with Телогеновый эффлувиум?
Based on 11 studies with 317 participants, there is moderate evidence from clinical studies that Омега-3 жирные кислоты may support Телогеновый эффлувиум management. Our evidence grade is B (Good Evidence).
How much Омега-3 жирные кислоты should I take for Телогеновый эффлувиум?
Studies have used various dosages. A commonly studied range is 250-500 mg EPA+DHA/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Омега-3 жирные кислоты?
Reported side effects may include Fishy aftertaste or burping, Mild gastrointestinal upset (nausea, diarrhea), Possible increased bleeding time at high doses, Unpleasant body odor at very high doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Омега-3 жирные кислоты and Телогеновый эффлувиум?
We rate the evidence as Grade B (Good Evidence). This rating is based on 11 peer-reviewed studies with 317 total participants. The overall direction of effect is positive.
Related Evidence
Другие ингредиенты для Телогеновый эффлувиум
Омега-3 жирные кислоты для других состояний
References
- [1] Michael M Ong et al.. Am J Clin Dermatol. 2026. Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations. doi:10.1007/s40257-025-00990-4 PubMed
- [2] Sarah Schaffer et al.. Cureus. 2025. A Scoping Review of Exosome Delivery Applications in Hair Loss. doi:10.7759/cureus.81152 PubMed
- [3] Azhar Ahmed et al.. Skin Appendage Disord. 2025. Herbal Remedies for Hair Loss: A Review of Efficacy and Safety. doi:10.1159/000542876 PubMed
- [4] Robert J Vanaria et al.. J Cosmet Dermatol. 2025. The Use of Light-Based Therapies in the Treatment of Alopecia. doi:10.1111/jocd.70434 PubMed
- [5] Boutros Soutou et al.. Indian J Dermatol. 2024. Iron Supplementation May Improve the Patient's Level of Satisfaction in Not-Low-Ferritin Telogen Effluvium: A Real-Life Observational Study. doi:10.4103/ijd.ijd_744_22 PubMed
- [6] S Cedirian et al.. J Cosmet Dermatol. 2023. Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic … doi:10.1111/jocd.15873 PubMed
- [7] Kabir Sardana et al.. J Cosmet Dermatol. 2022. Role of nutritional supplements in selected dermatological disorders: A review. doi:10.1111/jocd.14436 PubMed
- [8] Kavita Poonia et al.. J Cosmet Dermatol. 2019. NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India. doi:10.1111/jocd.12559 PubMed
- [9] Jana Zímová et al.. Acta Dermatovenerol Croat. 2016. Trichotillomania: Bizzare Patern of Hair Loss at 11-Year-old Girl. PubMed
- [10] N V Tsiskarishvili et al.. Georgian Med News. 2007. [Effectiveness of the treatment plan for androgenetic alopecia]. PubMed
- [11] R M Trüeb. Ther Umsch. 2002. [Diffuse hair loss in women]. doi:10.1024/0040-5930.59.5.217 PubMed
- [12] D H Rushton. Dermatol Clin. 1993. Management of hair loss in women. PubMed
Отказ от ответственности FDA: Данные утверждения не были оценены Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов (FDA). Продукты и информация на этом сайте не предназначены для диагностики, лечения, излечения или профилактики каких-либо заболеваний. Представленные оценки доказательности основаны на нашем анализе опубликованных рецензируемых исследований и не являются медицинской консультацией. Всегда консультируйтесь с лечащим врачом перед началом приёма любых добавок.